Next-Gen Stem Cell Therapies

Hematopoietic Stem Cells (HSCs)

Advancing new treatments for patients with blood cancers

Tacitus Therapeutics is a clinical-stage biotechnology company with a mission to develop stem cell therapies for life-threatening diseases. Our unique platform technology for cell expansion, differentiation, and engineering of HSCs enables us to advance the next generation of treatments for cancer patients. Expanded HSCs target unmet clinical needs associated with delayed engraftment, graft failure, and transplant rejection. HSCs are also the starting point for development of our first-in-class megakaryocyte treatment for patients requiring repeated platelet transfusions, and for future engineered cell therapies targeting rare diseases.

Pipeline

HSC100 — Lead Program Targeting Hematological Malignancies

MEG100 — Lead Program Targeting Thrombocytopenia

Advancing new treatments for patients with blood cancers
Icon

Addressing Life-Threatening Diseases

  • HSC100, Tacitus Therapeutics’ lead clinical program, is being investigated as allogeneic stem cell grafts for treatment of blood cancers, also known as hematological malignancies.
  • MEG100, our preclinical program in development, addresses prevention and/or treatment of low platelet counts, also known as thrombocytopenia typically occurring in patients with blood cancer.

Platform Technology

Cell Expansion

Significantly increase the number of engraftable HSCs collected from umbilical cord blood, peripheral blood, and bone marrow.

Cell Differentiation

Generate megakaryocytes from HSCs to enable the patient’s own body to durably produce platelets instead of repeated donor platelet transfusions.

Cell Engineering

Modification of expanded HSCs to develop cellular gene therapy products targeting rare diseases.

Hematologic malignancies are cancers that affect the body’s blood, bone marrow, or lymphatic systems. They are the fifth most commonly occurring cancers and the second leading cause of cancer death. The most common forms of hematologic cancers include leukemia, lymphoma, and multiple myeloma.

Thrombocytopenia is a medical condition that occurs when a patient does not have enough platelets in his or her blood, resulting in a high risk for bleeding. Thrombocytopenia can be inherited or can be caused as a result of several conditions or medications. Circulating platelets can be reduced by decreased platelet production, increased destruction, or being trapped in the spleen. Sometimes a drug confuses the immune system and makes it destroy platelets. Examples include heparin, quinine, sulfa-containing antibiotics, and anticonvulsants.